Search results
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
Zacks via Yahoo Finance· 1 month agoMannKind (MNKD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates --...
MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoMannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for...
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics UTHR reported third-quarter 2022 adjusted earnings of $4.91 per share, which...
When Will MannKind Corporation (NASDAQ:MNKD) Breakeven?
Simply Wall St. via Yahoo Finance· 10 months agoWe feel now is a pretty good time to analyse MannKind Corporation's (NASDAQ:MNKD) business as it...
7 Overvalued Penny Stocks to Sell Before June 2023
InvestorPlace via Yahoo Finance· 1 year agoWhile there are plenty of bargains to buy among penny stocks, there are also a good amount of overvalued penny stocks to sell. While significantly...
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
InvestorPlace via Yahoo Finance· 9 months agoPharma stocks can be a great way to add profits to your investment account. Companies that make...
7 Biotech Stocks to Sell in July
InvestorPlace via Yahoo Finance· 11 months agoBiotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit...
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same....
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso,...
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
Zacks via Yahoo Finance· 1 year agoUnited Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same....